An important Phase III, randomized, placebo-controlled trial (Sequential Tarceva in Unresectable NSCLC [SATURN]) that is investigating the role of maintenance therapy with erlotinib in EGFR IHC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback